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Received August 29, 2014; accepted September 29, 2014AbstractBackground: Human induced pluripotent stem cells (iPSCs) morphologically and functionally resemble human embryonic stem cells, which
presents the opportunity to use patient-specific somatic cells for disease modeling and drug screening. In order to take one step closer to clinical
applications, it is important to generate iPSCs through a less invasive approach and from any accessible tissue, including peripheral blood.
Meanwhile, how to differentiate blood cell-derived iPSCs into neuron-like cells is still unclear.
Methods: We utilized EpsteineBarr nuclear antigen-1-based episomal vectors, a nonviral system that can reprogram somatic cells into iPSCs in
both feeder-dependent and feeder-free conditions, to generate iPSCs from T cells via electroporation and then induce them into neuronal cells.
Results: We successfully isolated sufficient T cells from 20 mL peripheral blood of the donors and reprogrammed these T cells into iPSCs within
4 weeks. These iPSCs could be stably passaged to at least 50 passages, and exhibited the abilities of pluripotency and multiple-lineage dif-
ferentiation. Notably, under the medium induction for 21 days, these T-cell-derived iPSCs could be differentiated into Nestin (neural progenitor
marker)-, GFAP (glial cell marker)-, and MAP2 (neuron cell marker)-positive cells detected by immunofluorescence methods.
Conclusion: We have developed a safer method to generate integration-free and nonviral human iPSCs from adult somatic cells. This induction
method will be useful for the derivation of human integration-free iPSCs and will also be applicable to the generation of iPSCs-derived neuronal
cells for drug screening or therapeutics in the near future.
Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Reprogramming human differentiated cells into induced
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for disease modeling, pathophysiology studies, drug screening,
and cell-based therapies.1 iPSCs have been generated from
many types of somatic cells by induction of viral vectors
expressing defined reprogramming factors since 2007.2,3 The
genome-integrating viral vectors may produce insertional mu-
tations or even result in increasing the risk of tumor formation.4,5
Unfortunately, the use of viral vectors raises serious clinical
safety concerns, which have been tragically demonstrated in
several clinical gene therapy trials.6,7 To address these issues,
many alternatives, such as nonviral and genomic integration-ociation. All rights reserved.
354 P.-H. Tsai et al. / Journal of the Chinese Medical Association 78 (2015) 353e359free methods that are potentially safer, have been recently re-
ported, for example, using electroporation of nonintegrating
plasmids, small molecule modulators, recombinant proteins,
minicircle DNA vectors, and synthetic messenger RNA.8e10
So far, fibroblasts have been the most commonly used cells
in the generation of iPSCs. The use of fibroblasts is still
suboptimal for large-scale clinical application, due to the
invasive skin biopsies and the time-wasting process for
establishing stable cell lines from primary tissue.11 Generation
of human iPSCs from blood mononuclear cells (MNCs) has
been widely accepted as a more convenient, less invasive, and
almost unlimited resource for cell reprogramming, compared
to dermal fibroblasts.12 In general, establishing a primary cell
culture from skin biopsy takes several weeks. Additionally,
large numbers of frozen blood samples are stored in bio-
repositories worldwide.13,14 Many studies have successfully
generated iPSCs from human immature MNCs expressing
specific-markers, such as CD34.14 The immature MNCs, iso-
lated from umbilical cord blood, peripheral blood, and bone
marrow, were reprogrammed by transduction of four (Oct4,
Sox2, c-Myc, and Klf4) or fewer reprogramming genes via
retroviral system.13,15 Since T cells are the most abundant cells
in peripheral blood MNCs (PBMNCs), Seki et al isolated
PBMNCs and stimulated the expansion of T cells with an anti-
CD3 antibody and IL-2.12 However, the low efficiency of these
methods of generating iPSC, and reprogramming factor-
encoded oncogenes such as c-Myc was noted.16 Recently,
EpsteineBarr nuclear antigen-1 (EBNA-1)-based episomal
plasmid was one of the methods used for deriving non-
integrating iPSCs.17 This system may allow modification of
the reprogramming factors and enable relatively high and
long-term expression of the reprogramming factors.17,18
Accumulating studies have shown that a wide range
of donor cells, gene-delivery vehicles, and combinations of
reprogramming factors can be used for generating iPSCs.
Among them, minimally invasive and maximally safe methods
provide significant practical advantages for generating human
iPSCs. In this study, we isolated T cells from donors and
subsequently reprogrammed the obtained T cells into iPSCs.
Using the electroporation method, blood T cells from adult
humans have been reprogrammed into iPSCs with integration-
free EBNA-1 episomal vectors. Importantly, these iPSCs could
be differentiated into neuron cells under the 21 days of
medium-based induction. The platform of T-cell-based iPSCs
provided an alternative cell source and strategy for integration-
free iPSC generation without viral infection. Notably, the
neuronal cells differentiated from T-cell-based iPSCs may be
employed as an expandable platform for investigating patho-
genesis, in-vitro drug screening and therapeutics for neuro-
degeneration in the near future.
2. Methods2.1. T cell isolationThis study was carried out in compliance with the Helsinki
Declaration. Peripheral blood mono-nuclear cells (PBMCs)were isolated from six donors whose written informed con-
sents were obtained in accordance to the guidelines of the
Institutional Review Board (Taipei Veterans General Hospi-
tal). This study was approved by our Institutional Review
Board (VGHIRB 2014-05-002C). The patients were all
documented as deceased prior to our data review. In brief, one
ratio of blood sample was layered on one ratio of Ficolle-
Plaque Plus, and the pellet (400g, 30 minutes at 20C) and
buffy coat were collected, washed twice with phosphate
buffered saline (PBS), and cultured in Dulbecco's modified
Eagle's medium (DMEM; SigmaeAldrich Corporation, St.
Louis, MO, USA) with 100 IU/mL of penicillin, 100 mg/mL of
streptomycin and 10% v/v fetal bovine serum (PAA, Pasching,
Austria).2.2. T cell stimulationT cells were expanded in freshly prepared AIM-V medium
(Invitrogen, Carlsbad, CA, USA) supplemented with peni-
cillin/streptomycin/glutamine (Invitrogen) plus 300 IU/mL
rhIL2 (Peprotech) and 10 ng/mL soluble anti-CD3 antibody
(OKT3 clone; eBioscience).192.3. Human iPSC generation and cultureTo generate integration-free iPSCs, T cells were nucleo-
fected with 3 mg expression plasmid mixture using Amax-
aTM human T Cell NucleofectorTM Kit (Lonza). In each
nucleofection, 2  106 cells T cells were treated by 0.83 mg
PCXLE-hOCT3/4-shp53, 0.83 mg PCXLE-hSK, 0.83mg
pCXLE-hUL, and 0.5 mg pCXWB-EBNA1. The plasmids
were all obtained from Addgene (https://www.addgene.org/):
pCXLE-hOCT3/4-shp53-F (plasmid 27077); pCXLE-hSK
(plasmid 27078); pCXLE-hUL (plasmid 27080); and
pCXWB-EBNA1 (plasmid 37624). Cells were then cultured,
and freshly thawed inactivated mouse embryonic fibroblasts
(MEFs) feeder cells were added into each well every 10e14
days. The number of alkaline phosphate-positive iPSC col-
onies was counted at 3e4 weeks interval after nucleofection.
Undifferentiated iPSCs were maintained on inactivated MEFs
(50,000 cells/cm2) in human embryonic stem cell (ESC)
medium: DMEM/F12 (Gibco) supplemented with 20%
KnockOut serum replacer (KSR; Invitrogen), 0.1mM nones-
sential amino acids (Invitrogen), 1mM L-glutamine, 0.1mM
b-mercaptoethanol, 10 ng/mL recombinant human basic
fibroblast growth factor, and antibiotics (Gibco). To prevent
cell contamination by MEFs, these iPSCs were transferred to
feeder-free/serum-free culture in HESF V2 medium (Cell
Science & Technology) without KSR supplementation, as
described previously.202.4. Quantitative reverse transcription polymerase chain
reactionSYBR-green was used for real-time reverse transcription
polymerase chain reaction (RT-PCR) detection. Briefly, total
RNA (1 mg) of each sample was reverse-transcribed in 20 mL
Fig. 1. (A) Clinical characteristics of donors' isolation and characterization of
CD3þ T cells. (B) After 3 days in expansion/selection medium, PBMCs were
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trogen). Amplification was carried out in a total volume of
20 mL containing 0.5mM of each primer, 4mM MgCl2, 2 mL
LightCyclereFastStart DNA Master SYBR green I (Roche
Diagnostics GmbH, Mannheim, Germany), and 2 mL of 1:10
diluted cDNA. All reactions were performed in triplicate. The
transcript levels of genes were standardized to the corre-
sponding GADPH level, and for each candidate gene, mRNA
levels relative to the highest candidate gene level were esti-
mated in percentages.2.5. ImmunofluorescenceThe living cells and spheres were fixed in 4% para-
formaldehyde, permeabilized in 0.1% Triton X-100, and
blocked in 5% normal goat serum-PBS. Cells were incubated
with primary antibodies, washed three times in PBS, and then
incubated with goat antimouse or secondary antibodies con-
jugated with Fluorescein isothiocyanate (FITC) (green) or
Phycoerythrin (PE) (red). The 4',6-diamidino-2-phenylindole
(DAPI) was used as a nuclear stain (blue). Images were ob-
tained using fluorescent microscopy and a digital camera. The
antibodies that were used are listed in Table S1.2.6. Induced differentiation of T-iPSCs into neuron-like
cellsThere were 1  105 iPSCs at the fifth to eighth passage that
were treated with a serum-free modified neurogenic selection
medium for 2 weeks. The serum-free medium for the selection
of neural precursor cells contained DMEM/F12 1:1 (Gibco/
BRL) and was supplemented with 0.6% glucose, 25 mg/mL
insulin, 100 mg/mL transferrin, 20nM progesterone, 60mM
putrescine, 30nM selenium chloride, 2mM glutamine, 3mM
sodium bicarbonate, 5mM HEPES, 2 mg/mL heparin, 20 ng/
mL epidermal growth factor, and 20 ng/mL basic fibroblast
growth factor (all from Sigma). For further neural differenti-
ation, epidermal growth factor was removed from the medium,
and the medium was supplemented with 20 ng/mL SHH
(Sonic hedgehog) (R&D), 10 ng/mL BDNF (Brain-derived
neurotrophic factor) (R&D), and with alletrans-retinoic acid
(100nM) for another 7 days.212.7. Statistical analysisThe results are represented as mean ± standard deviation.
Statistical analyses were performed using t test for comparing
two groups. One-way or two-way analysis of variance, and
Bonferroni test were used to detect differences among three or
more groups. Results with p < 0.05 were considered statisti-
cally significant.highly proliferative. Phase contrast microscopy, magnification 200. (C) Flow
cytometric analysis of PBMCs gated on the CD3þ cell population. (D)
Quantitative analysis of CD3þ positive cells in PBMCs (n ¼ 6) in each group.
Data are presented as mean ± standard deviation of three independent ex-
periments. *p < 0.05 versus Day 0.
356 P.-H. Tsai et al. / Journal of the Chinese Medical Association 78 (2015) 353e3593. Results3.1. Isolation and characterization of T cells from
peripheral bloodAs shown in Fig. 1A, peripheral blood was obtained from
six donors ranging in age from 23 years to 38 years.
PBMNCs mainly consist of T lymphocytes, but also include
B lymphocytes, monocytes, and macrophages. We further
culture the isolated PBMNCs by plate-bound anti-CD3
monoclonal antibody and IL-2 for T cell expansion. Anti-
CD3 antibody modulates the TCR-CD3 complex to induce
T cell proliferation and activation, whereas IL-2 also acti-
vates general T cell signaling pathways and eventually pro-
motes cytokine transcription, cell survival, cell-cycle entry,
and growth. Our data show that the number of cells in the
cultured PBMCs was apparently increased (Fig. 1B). In order
to characterize these cells, the expression of CD3 protein (the
complex of TCR proteins on the surface of T cells) was
used as a T cellespecific marker. At Day 3 of culture withFig. 2. Generation and characterization of iPSCs derived from patients with AMD
episomal plasmids via electroporation. (B) Phase-contrast photomicrograph and (C)
Data presented are derived from donor No. 1 and No. 3. (D) Immunofluorescence sta
NANOG, and TRA-1-81) in undifferentiated T-iPSCs. Nuclei were counterstained w
qRT-PCR results indicated an ESC-like gene expression pattern in representative col
cell; iPSCs ¼ human induced pluripotent stem cells; qRT-PCR ¼ quantitative revanti-CD3 monoclonal antibody and IL-2, CD3-positive cells
had increased up to ~90% of cultured PBMCs (Figs. 1C
and 1D).3.2. Characterization of iPSC generation from T cellsThe development of novel approaches for generating
integration-free iPSCs has eliminated integrating virus-
associated genotoxicity in clinical applications. In this study,
we used EBNA1-based episomal vectors, a nonviral system
that can reprogram somatic cells into iPSCs in both feeder-
dependent and -free conditions, to generated iPSCs from T
cells via electroporation (Fig. 2A). The ESC-like colonies
began to emerge 28 days after the plasmid transfection and
were selected for expansion. Established clones formed flat
and compacted colonies, showed high nucleus-to-cytoplasm
ratios, stained positive for alkaline phosphate, and exhibited
morphology indistinguishable from that of human ESCs (Figs.
2B and 2C). As shown by immunofluorescence, selected
clones exhibited the stemness signature and revealed theand unaffected control. (A) Schematic diagram of the reprogramming with
alkaline phosphatase activity of undifferentiated T-iPSCs. Scale bar ¼ 100 mm.
ining demonstrated the expression of pluripotency markers (OCT4, TRA-1-61,
ith DAPI (4',6-diamidino-2-phenylindole) (blue). Scale bar ¼ 200 mm. (E) The
onies of iPSCs. T cells were used as a negative control. ESC ¼ embryonic stem
erse transcription polymerase chain reaction.
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these T-cell derived iPSCs (Fig. 2D). RT-PCR also showed that
both Ctrl- and AMD-iPSCs expressed various stemness genes,
such as Oct4, Sox2, klf4, Nanog, REX, DPPA2, and GDF3,
identical to those observed in H9 human ESC lines (Fig. 2E).
Taken collectively, these results demonstrate that fully
reprogrammed iPSCs with pluripotent propensity can be
effectively derived from T cells.3.3. Differentiation of human T cell-derived iPSCs into
neural progenitor cellsWe followed previously established methods for differen-
tiating iPSCs into neural progenitors. Both the iPSCs and
ESCs were separated from the feeder fibroblasts before dif-
ferentiation.22 Fig. 3A shows representative morphological
features of neurospheres following attachment, with extensive
neurite outgrowth at the periphery of neurospheres. Immu-
nostain demonstrated that the differentiated cells consisted of
mature neurons. Three weeks after the neural induction,Fig. 3. Differentiation of T-iPSC into neural cells. (A) Immunofluorescence staini
fluorescence staining for neuronal marker Nestin and MAP2 demonstrated mo
bar ¼ 200 mm. (C, D) Expression of neural-specific genes during the differentiation
analysis showed that the expression pattern of T-iPSCs-Neus was closer to the gene
horizontal axis; Unit: D-chip unit) was used to measure the expression profiling
induced pluripotent stem cells; SOX2 ¼ Ssex determining region Y-box 2; GFA
NCAM ¼ neural cell adhesion molecule.T-iPSC-derived neurons (T-iPSC-Neus) formed extensive
networks and showed positively stained Nestin, as well as the
mature neuronal marker MAP2 (Fig. 3B). Quantitative real-
time RT-PCR analysis revealed that the expression of
neuron-specific markers, including Nestin, GFAP, MAP2, and
NCAM1 were initially upregulated in T-iPSC-Neus after in-
duction of neural differentiation for 10 days and 20 days (Figs.
3C and 3D). The mRNA expressions of these neuron-specific
markers were statistically increased during the course of dif-
ferentiation. Multidimensional scaling (Fig. 3E) further
showed that the gene expression pattern of T-iPSC-Neus was
closer to the gene signature of ESC-neurons. Altogether, these
data support that T-iPSCs could present pluripotent potential
and differentiate into neuron-like cells.
4. Discussion
Recently, patient-specific neural cells derived from human
somatic cells have been revolutionizing the study of neuro-
degeneration diseases and holding great hope for futureng for Nestin and Sox2 in neurospheres. Scale bar ¼ 100 mm. (B) Immuno-
rphology and neurons formed extensive networks in T-iPSCs-Neus. Scale
course of T-iPSC-Neus for 10 days and 20 days. (E) Multidimensional scaling
signature of ESC-Neus. Principal component analysis (PC1: vertical axis; PC2:
using bioinformatics methods. ESC ¼ embryonic stem cell; iPSCs ¼ human
P ¼ glial fibrillary acidic protein; MAPs ¼ microtubule-associated proteins;
Table 1
Comparison of human iPSCs derived from different somatic cell types.
Cell type Fibroblast Dental pulp cell T cell
Source Skin biopsy Teeth Peripheral
blood
Invasive High High Low
Length of isolation 3e4 wk 3e4 wk 3 d
Length of reprogramming 3 wk 3e4 wk 3e4 wk
Efficiency of reprogramming 0.02% 0.01% < 0.01%
iPSCs ¼ human induced pluripotent stem cells.
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be carried out using readily accessible sources of somatic cells
from patients for reprogramming, for instance, skin fibroblasts,
hair keratinocytes, epithelial cells found in urine, and dental
pulp.23e26 The majority of iPSC studies have focused on taking
fibroblasts as the somatic cell source, the most invasive yet the
least suitable approach. In our previous study, we demonstrated
that dental pulps cells from deciduous and permanent teeth could
be reprogrammed into iPSCs without c-Myc. Moreover, these
iPSCs were capable of differentiating into neuron-like cells.
Although dental pulp cells from teeth provide another source of
cells for reprogramming, collecting dental pulp cells from teeth
could be a limiting factor for scaled production. Reciprocally,
PBMNCs have been widely accepted as a more convenient and
almost unlimited resource for cell reprogramming, due to the
ease of obtaining patient samples.11,12 Several studies have
established iPSCs from PBMNCs, and successfully differenti-
ated PBMNCs-derived iPSCs into mesenchymal stems cells,
cardiomyocytes, and hepatocytes.27e29 It has been well docu-
mented that the generation of human iPSCs from blood MNCs
offers several advantages over other cell sources (Table 1). It is
more convenient and less invasive to obtain peripheral blood
than dermal fibroblasts and dental pulp. This new approach saves
several weeks of cell preparation because T cells are not required
to establish a primary cell culture like skin biopsy. We suc-
cessfully isolated sufficient T cells from only 20 mL peripheral
blood of the donors and reprogrammed these T cells into iPSCs.
These iPSCs could be stably passaged to at least 50 passages and
retained their pluripotency and ability for tridermal differentia-
tion. Subsequently, we differentiated these iPSCs into neuron-
like cells. These features enabled the use of these patient-
specific neuron-like cells as a malleable platform for investi-
gating the mechanisms of diseases and drug screening in vitro.
To make human iPSCs amenable to clinical applications,
several challenges remain to be addressed. Previously devised
strategies for production of iPSCs have so far been mainly
through retroviral vectors and constitutive lentiviral systems.
These viral systems hampered the clinical use of iPSCs, due to
genetic variability that is caused by random integration of
multiple pro-viral copies.4,5 Therefore, it is necessary to pursue
nonintegration approaches.30 In this study, we generated
patient-specific iPSCs via integration-free episomal vectors
instead of integrating viral vectors. EBNA1 is amultifunctional,
dimeric viral protein associated with EpsteineBarr virus. These
episomal vectors based on the EBNA1 have been proven to
generate iPSCs very efficiently without the risk of transgenicsequences being inserted into the target cell genome. Our data
demonstrate that the proliferation of T cells could be activated
by the combination of IL-2 and anti-CD3 antibodies. iPSC in-
duction was greatly enhanced when we used the extra EBNA1
vector and the Y4 combination in the T-cell stimulating me-
dium. Encouragingly, this method represented one step closer to
the clinical application of iPSC-based cell therapy.
In this study, we developed a novel method for generating
iPSCs from PMNCs, which is highly convenient and far less
invasive, compared to the traditional means. Only a few mil-
liliters of peripheral blood are sufficient for the generation of
iPSCs. Accordingly, our report provides a very practical and
extremely efficient way to generate patient-specific iPSCs.
This will be of great potential for the derivation of human
integration-free iPSCs, and will also be applicable to the
generation of clinical-grade iPSCs hereafter.
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